Wen Xu

Dr. Wen Xu

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Suowen XuSuowen Xu
Suowen Xu
XWXiumei Wu
Xiumei Wu
SWSichen Wang
Sichen Wang
MXMengyun Xu
Mengyun Xu
TFTingyu Fang
Tingyu Fang
Jianping WengJianping Weng
Jianping Weng
Nonalcoholic fatty liver disease (NAFLD) encompasses a disease continuum from simple steatosis to nonalcoholic steatohepatitis (NASH). However, there are currently no approved pharmacotherapies for NAFLD, although several drugs are in advanced stages of clinical development. Because of the complex pathophysiology and heterogeneity of NAFLD, the identification of potential therapeutic targets is clinically important. Here, we demonstrated that tripartite motif 56 (TRIM56) protein abundance was markedly downregulated in the livers of individuals with NAFLD and of mice fed a high-fat diet. Hepatocyte-specific ablation of TRIM56 exacerbated the progression of NAFLD, while hepatic TRIM56 overexpression suppressed it. Integrative analyses of interactome and transcriptome profiling revealed a pivotal role of TRIM56 in lipid metabolism and identified the lipogenesis factor fatty acid synthase (FASN) as a direct binding partner of TRIM56. TRIM56 directly interacted with FASN and triggered its K48-linked ubiquitination–dependent degradation. Finally, using artificial intelligence–based virtual screening, we discovered an orally bioavailable small-molecule inhibitor of FASN (named FASstatin) that potentiates TRIM56-mediated FASN ubiquitination. Therapeutic administration of FASstatin improved NAFLD and NASH pathologies in mice with an optimal safety, tolerability, and pharmacokinetics profile. Our findings provide proof of concept that targeting the TRIM56/FASN axis in hepatocytes may offer potential therapeutic avenues to treat NAFLD.

1 January 2021 in International Journal of Hyperthermia
Verified
Journal Article
Open access
NWNana Wang
Nana Wang
BZBowen Zheng
Bowen Zheng
TWTao Wu
Tao Wu
LTLei Tan
Lei Tan
YLYufan Lian
Yufan Lian
RJRen Jie
Ren Jie
Radiofrequency ablation (RFA) has been recommended as the treatment for benign thyroid nodules (BTNs) by some guidelines. However, detailed follow-up instructions for thyroid function about the tim...

2 July 2022 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
ZLZiyu Liu
Ziyu Liu
CWChaofan Wang
Chaofan Wang
DYDaizhi Yang
Daizhi Yang
SLSihui Luo
Sihui Luo
YDYu Ding
Yu Ding
JYJinhua Yan
Jinhua Yan
Aims/Introduction: Peer support for diabetes has become convenient and interactive after the emergence of mobile health (mHealth). We aimed to evaluate the association between engagement in peer support through the mHealth app and glycemic control in type 1 diabetes patients.Materials and Methods: This retrospective study included adults with type 1 diabetes who had joined the mobile community “TangTangQuan” since May 2018 for at least 1 year. “Like”, “comment” and “share” were the major interaction indicators of the mobile community and were used to assess engagement in peer support. The patients were divided into four engagement groups by quartile. The primary outcome was the change in glycosylated hemoglobin (HbA1c), mean fasting blood glucose (FBG) and postprandial blood glucose (PBG) from baseline to the 12th month. Other outcomes included the change of self‐monitoring of blood glucose frequency, hypoglycemia frequency and the proportion of reaching optimal glycemic control.Results: Among the 693 individuals, the HbA1c, mean FBG and PBG improved in the 12th month. Multiple regression analysis showed that higher engagement in peer support was associated with a greater reduction of HbA1c (β = −0.45, P < 0.001) and mean FBG (β = −0.82, P < 0.001). In the subgroup of poor glycemic control, the association between engagement in peer support and glycemic improvement still remained (HbA1c: β = −0.86, P = 0.002; FBG: β = −1.36, P = 0.001). The engagement in mobile peer support was positively correlated with educational level (odds ratio 1.42, P = 0.042), household income (odds ratio 1.43, P = 0.013) and the use of continuous subcutaneous insulin infusion (odds ratio 1.73, P = 0.009).Conclusion: High engagement in mobile peer support was associated with better glycemic control in adults with type 1 diabetes.

5 December 2018 in Journal of Diabetes
Verified
Journal Article
Open access
PDF file
HDHongrong Deng
Hongrong Deng
SLShuo Lin
Shuo Lin
XYXubin Yang
Xubin Yang
JLJing Lv
Jing Lv
SLSihui Luo
Sihui Luo
OGOn Behalf of the CONFIDENCE Group
On Behalf of the CONFIDENCE Group
Background: The weight‐reducing effect of exenatide has been proved, but too much weight loss in normal‐weight patients may concern physicians. This study evaluated the effects of exenatide monotherapy on glycemic control and weight change in normal‐weight, overweight, and obese patients with newly diagnosed type 2 diabetes (T2D).Methods: In this multicenter prospective study, 29 normal‐weight, 54 overweight, and 27 obese newly diagnosed and drug‐naïve patients with T2D were treated with exenatide for 48 weeks. The primary efficacy endpoint was the effect of baseline body mass index (BMI) on glycemic control, measured as the change in HbA1c from baseline to Week 48 compared among different BMI groups. Other endpoints included comparisons of the effects of exenatide on fasting plasma glucose (FPG), postprandial plasma glucose (PPG), body weight, and other metabolic indices.Results: After 48‐week treatment, the estimated mean changes in HbA1c in normal‐weight, overweight, and obese patients were −1.9%, −1.8%, and −1.5%, respectively (P = 0.290 among groups after adjustment for baseline values). There were similar declines in FPG and 0.5‐ and 2‐hour PPG among groups. There were non‐significant trends from normal‐weight to overweight to obese patients for increased weight reduction (decreases of 2.2, 3.9, and 4.0 kg, respectively; P = 0.104) and changes in waist circumference (decreases of 2.2, 3.2, and 5.6 cm, respectively; P = 0.078).Conclusions: Baseline BMI had no effect on glycemic control, weight change, or other metabolic indices with exenatide monotherapy. Normal‐weight patients with T2D would benefit from exenatide as much as overweight or obese patients on glucose control, without increased risk of excess weight loss.

26 March 2022 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
YLYanli Li, Li
Yanli Li, Li
YCYalan Chen
Yalan Chen
ZLZiyu Liu
Ziyu Liu
BLBeisi Lin
Beisi Lin
XDXiaoyi Deng
Xiaoyi Deng
WXWen Xu
Wen Xu

15 October 2024 in World Journal of Diabetes
Verified
Journal Article
Open access
BLBei-Si Lin
Bei-Si Lin
ZLZhi-Gu Liu
Zhi-Gu Liu
DCDan-Rui Chen
Dan-Rui Chen
YYYan-Ling Yang
Yan-Ling Yang
DYDai-Zhi Yang
Dai-Zhi Yang
WXWen Xu
Wen Xu
BACKGROUND In patients with type 2 diabetes mellitus (T2DM), the risk of hypoglycemia also occurs in at a time-in-range (TIR) of > 70%. The hemoglobin glycation index (HGI) is considered the best single factor for predicting hypoglycemia, and offers new perspectives for the individualized treatment of patients with well-controlled blood glucose levels that are easily ignored in clinical settings. AIM To investigate the relationship between HGI and hypoglycemia and the implications of HGI on hypoglycemia in T2DM with TIR > 70%. METHODS All participants underwent a 7-days continuous glucose monitoring (CGM) using a retrospective CGM system. We obtained glycemic variability indices using the CGM system. We defined HGI as laboratory hemoglobin A1c minus the glucose management indicator. Patients were categorized into low HGI (HGI < 0.5) and high HGI groups (HGI ≥ 0.5) according to HGI median (0.5). Logistic regression and receiver operating characteristic curve analyses were used to determine the risk factors for hypoglycemia. RESULTS We included 129 subjects with T2DM (54.84 ± 12.56 years, 46% male) in the study. Median TIR score was 90%. The high HGI group exhibited lower TIR and greater time below range with higher hemoglobin A1c than the low HGI group; this suggests more glycemic excursions and an increased incidence of hypoglycemia in the high HGI group. Multivariate analyses revealed that mean blood glucose, standard deviation of blood glucose and HGI were independent risk factors for hypoglycemia. Receiver operating characteristic curve analysis indicated that the HGI was the best predictor of hypoglycemia. In addition, the optimal cut-off points for HGI, mean blood glucose, and standard deviation of blood glucose in predicting hypoglycemia were 0.5%, 7.2 mmol/L and 1.4 mmol/L respectively. CONCLUSION High HGI was significantly associated with greater glycemic excursions and increased hypoglycemia in patients with TIR > 70%. Our findings indicate that HGI is a reliable predictor of hypoglycemia in this population.